Publication Name	World Journal of Radiology
Manuscript ID	15097
Country	Italy

Received	2014-11-08 12:01
Peer-Review Started	2014-11-09 15:35
To Make the First Decision	2014-12-12 17:35
Return for Revision	2014-12-18 15:41
Revised	2015-01-15 05:24
Second Decision	2015-01-28 12:07
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-02-09 10:33
Articles in Press	2015-02-09 10:33
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-03-14 15:21
Publish the Manuscript Online	2015-03-24 17:23

ISSN	1949-8470 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Editorial
Article Title	Metformin and cancer: Technical and clinical implications for FDG-PET imaging
Manuscript Source	Invited Manuscript
All Author List	Selene Capitanio, Cecilia Marini, Gianmario Sambuceti and Silvia Morbelli
Funding Agency and Grant Number
Corresponding Author	Silvia Morbelli, Full Staff, Nuclear Medicine Unit, IRCCS AOU San Martino-IST, Department of Health Sciences, University of Genoa, L.go R. Benzi, 10, 16132 Genova, Italy. silviadaniela.morbelli@hsanmartino.it
Key Words	Metformin; Cancer; 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography; Diabetes; Glucose metabolism
Core Tip	Given the recent increasing number of clinical trials involving the use of metformin as anticancer agent and with the widespread use of 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET), this editorial deals with a critical evaluation of the main variables regulating FDG uptake that could be potentially influenced by the biguanide. This analysis could optimize not only the interpretation of PET images in diabetic patients but could also help to verify whether FDG-PET could be a valid tool to appreciate anticancer potential of this new therapeutic approach thus opening a new window on clinical trials.
Publish Date	2015-03-24 17:23
Citation	Capitanio S, Marini C, Sambuceti G, Morbelli S. Metformin and cancer: Technical and clinical implications for FDG-PET imaging. World J Radiol 2015; 7(3): 57-60
URL	http://www.wjgnet.com/1949-8470/full/v7/i3/57.htm
DOI	http://dx.doi.org/10.4329/wjr.v7.i3.57

Full Article (PDF)	WJR-7-57.pdf
Full Article (Word)	WJR-7-57.doc
Manuscript File	15097-Review.docx
Answering Reviewers	15097-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	15097-Conflict-of-interest statement.pdf
Copyright License Agreement	15097-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	15097-Language certificate.docx
Peer-review Report	15097-Peer-review(s).pdf
Scientific Misconduct Check	15097-Scientific misconduct check.pdf
Scientific Editor Work List	15097-Scientific editor work list.pdf